Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Chengdu Easton Biopharmaceuticals Co PS Ratio Related Terms
Chengdu Easton Biopharmaceuticals Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Easton Biopharmaceuticals Co PS Ratio Chart
SHSE:688513 vs VRTX, REGN, RVMD: PS Ratio Comparison
For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Easton Biopharmaceuticals Co PS Ratio vs Biotechnology Industry
Chengdu Easton Biopharmaceuticals Co PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Chengdu Easton Biopharmaceuticals Co's Share Price of today is ¥44.32. Chengdu Easton Biopharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥7.79.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a PS Ratio of 5.69 as of Jul. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. This is near median its historical median of 5.71. Over the past decade, Chengdu Easton Biopharmaceuticals Co's PS Ratio has ranged from 3.79 to 10.22. According to the industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #354 out of 930 companies in the Biotechnology industry, placing it in the top 38.1%.
Is Chengdu Easton Biopharmaceuticals Co's PS Ratio too high?
Chengdu Easton Biopharmaceuticals Co's current PS Ratio of 5.69 is near median its 10-year median of 5.71. Over the past 10 years, this metric has ranged from a low of 3.79 to a high of 10.22. The Biotechnology industry median PS Ratio is 8.89. Chengdu Easton Biopharmaceuticals Co's value of 5.69 is 36% below this industry median. Based on the distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #354 out of 930 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #354 out of 930 companies for PS Ratio. This puts Chengdu Easton Biopharmaceuticals Co in the upper half of its industry. The industry median PS Ratio is 8.89. Chengdu Easton Biopharmaceuticals Co's value of 5.69 is 36% below this benchmark. Historically, Chengdu Easton Biopharmaceuticals Co's own PS Ratio has ranged from 3.79 to 10.22 over the past decade. While the company's 10-year median is 5.71 vs. the industry median of 8.89, Chengdu Easton Biopharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 8.89, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chengdu Easton Biopharmaceuticals Co's current PS Ratio of 5.69 is 36% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. For the Biotechnology industry, the median PS Ratio is 8.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengdu Easton Biopharmaceuticals Co's current PS Ratio is 5.69, which is near median its own 10-year median of 5.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Fairly Valued. The stock's GF Value™ is ¥48.37, compared to a current price of ¥44.32 — trading 8.4% below its estimated fair value. The current PS Ratio is 5.69, which is near median its 10-year median of 5.71 and 36% below the Biotechnology industry median of 8.89. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current PS Ratio is 5.69 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥44.32 is trading 8.4% below its estimated GF Value™ of ¥48.37.
GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Fairly Valued.
Key valuation signals for SHSE:688513:
PS Ratio: 5.69 (near median its 10-year median of 5.71)
GF Value™: ¥48.37 vs. price of ¥44.32 (8.4% below fair value)
Industry Position: 36% below the Biotechnology median (#354 of 930)
No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Easton Biopharmaceuticals Co Business Description
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
88GF Score
Get the complete analysis for SHSE:688513
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688513 has been successfully added to your 
